LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 16

Search options

  1. Article ; Online: Characterization of a long-term mouse primary liver 3D tissue model recapitulating innate-immune responses and drug-induced liver toxicity.

    Nudischer, Ramona / Renggli, Kasper / Hierlemann, Andreas / Roth, Adrian B / Bertinetti-Lapatki, Cristina

    PloS one

    2020  Volume 15, Issue 7, Page(s) e0235745

    Abstract: Three-dimensional liver in vitro systems have recently attracted a lot of attention in drug development. These systems help to gain unprecedented insights into drug-induced liver injury (DILI), as they more closely reproduce liver biology, and as drug ... ...

    Abstract Three-dimensional liver in vitro systems have recently attracted a lot of attention in drug development. These systems help to gain unprecedented insights into drug-induced liver injury (DILI), as they more closely reproduce liver biology, and as drug effects can be studied in isolated and controllable microenvironments. Many groups established human-based in vitro models but so far neglected the animal equivalent, although the availability of both models would be desirable. Animal in vitro models enable back- and forward translation of in vitro and in vivo findings, bridge the gap between rodent in vivo and human in vitro scenarios, and ultimately support the interpretation of data generated with preclinical species and humans. Since mice are often used in drug development and physiologically relevant in vitro systems are lacking, we established, for the first time, a mouse liver model that encompasses primary parenchymal and non-parenchymal cells with preserved viability and functionality over three weeks. Using our three-dimensional liver spheroids, we were able to predict the toxicity of known DILI compounds, demonstrated the interaction cascades between the different cell types and showed evidence of drug-induced steatosis and cholestasis. In summary, our mouse liver spheroids represent a valuable in vitro model that can be applied to study DILI findings, reported from mouse studies, and offers the potential to detect immune-mediated drug-induced liver toxicity.
    MeSH term(s) Animals ; Anti-Bacterial Agents/toxicity ; Anti-Inflammatory Agents, Non-Steroidal/toxicity ; Cells, Cultured ; Chemical and Drug Induced Liver Injury/immunology ; Chemical and Drug Induced Liver Injury/metabolism ; Hepatocytes/metabolism ; Immunity, Innate ; Liver/drug effects ; Liver/pathology ; Mice ; Models, Biological ; Primary Cell Culture/methods ; Spheroids, Cellular/cytology ; Spheroids, Cellular/immunology ; Spheroids, Cellular/metabolism
    Chemical Substances Anti-Bacterial Agents ; Anti-Inflammatory Agents, Non-Steroidal
    Language English
    Publishing date 2020-07-09
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 1932-6203
    ISSN (online) 1932-6203
    DOI 10.1371/journal.pone.0235745
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Concurrent isolation of hepatic stem cells and hepatocytes from the human liver.

    Lee, Serene M L / Bertinetti-Lapatki, Cristina / Schiergens, Tobias S / Jauch, Karl-Walter / Roth, Adrian B / Thasler, Wolfgang E

    In vitro cellular & developmental biology. Animal

    2020  Volume 56, Issue 3, Page(s) 253–260

    Abstract: Hepatocytes differentiated from induced pluripotent stem cells or stem cells have the potential to be representative in vitro models of the human liver for research as well as early safety assessment programs. However, up until now, there has been no ... ...

    Abstract Hepatocytes differentiated from induced pluripotent stem cells or stem cells have the potential to be representative in vitro models of the human liver for research as well as early safety assessment programs. However, up until now, there has been no definitive proof that differentiated hepatocytes recapitulate the phenotype and functional characteristics of primary hepatocytes from the same individual. Thus, a method for the concurrent isolation of hepatocytes and hepatic stem cells is presented here to provide the cells necessary for the evaluation of the required benchmarking. The method presented here generated high-quality hepatocytes with a purity of 94 ± 1% and a high percentage viability of 79 ± 2%. Furthermore, the hepatic stem cells isolated were found to be actively proliferating and have a purity of 98 ± 1%. Thus, these isolated cells can be used as a powerful tool for the validation of differentiated hepatocyte in vitro models.
    MeSH term(s) Cell Separation/methods ; Epithelial Cell Adhesion Molecule/metabolism ; Hepatocytes/cytology ; Humans ; Keratin-19/metabolism ; Liver/cytology ; Liver Cirrhosis/pathology ; Stem Cells/cytology ; Stem Cells/metabolism
    Chemical Substances Epithelial Cell Adhesion Molecule ; Keratin-19
    Language English
    Publishing date 2020-03-27
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 1077810-x
    ISSN 1543-706X ; 0883-8364 ; 1071-2690
    ISSN (online) 1543-706X
    ISSN 0883-8364 ; 1071-2690
    DOI 10.1007/s11626-020-00433-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Concurrent isolation of hepatic stem cells and hepatocytes from the human liver

    Lee, Serene M. L / Bertinetti-Lapatki, Cristina / Schiergens, Tobias S / Jauch, Karl-Walter / Roth, Adrian B / Thasler, Wolfgang E

    In vitro cellular & developmental biology. 2020 Mar., v. 56, no. 3

    2020  

    Abstract: Hepatocytes differentiated from induced pluripotent stem cells or stem cells have the potential to be representative in vitro models of the human liver for research as well as early safety assessment programs. However, up until now, there has been no ... ...

    Abstract Hepatocytes differentiated from induced pluripotent stem cells or stem cells have the potential to be representative in vitro models of the human liver for research as well as early safety assessment programs. However, up until now, there has been no definitive proof that differentiated hepatocytes recapitulate the phenotype and functional characteristics of primary hepatocytes from the same individual. Thus, a method for the concurrent isolation of hepatocytes and hepatic stem cells is presented here to provide the cells necessary for the evaluation of the required benchmarking. The method presented here generated high-quality hepatocytes with a purity of 94 ± 1% and a high percentage viability of 79 ± 2%. Furthermore, the hepatic stem cells isolated were found to be actively proliferating and have a purity of 98 ± 1%. Thus, these isolated cells can be used as a powerful tool for the validation of differentiated hepatocyte in vitro models.
    Keywords functional properties ; hepatocytes ; humans ; induced pluripotent stem cells ; liver ; models ; phenotype ; safety assessment ; viability
    Language English
    Dates of publication 2020-03
    Size p. 253-260.
    Publishing place Springer US
    Document type Article
    ISSN 1071-2690
    DOI 10.1007/s11626-020-00433-w
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  4. Article ; Online: Usage of standardized antigen-presenting cells improves ELISpot performance for complex protein antigens.

    Navarrete, Marcelo A / Bertinetti-Lapatki, Cristina / Michelfelder, Ines / Veelken, Hendrik

    Journal of immunological methods

    2013  Volume 391, Issue 1-2, Page(s) 146–153

    Abstract: The enzyme-linked immunospot (ELISpot) assay is a widely used method for immune monitoring in cancer immunotherapy trials. In the ELISpot assay, peripheral blood mononuclear cells (PBMC) are stimulated with specific antigens, and cytokines of interest ... ...

    Abstract The enzyme-linked immunospot (ELISpot) assay is a widely used method for immune monitoring in cancer immunotherapy trials. In the ELISpot assay, peripheral blood mononuclear cells (PBMC) are stimulated with specific antigens, and cytokines of interest produced by individual cells are detected. In the standard procedure, T cells rely for antigen presentation on other cells like the monocyte/macrophage population present among the PBMC. Whereas oligopeptides can be added directly to the ELISpot assay without the necessity of a pre-incubation step, protein antigens must be internalized and processed by antigen-presenting cells to accomplish efficient presentation via HLA class I or II. We have studied the impact of sources for different antigen-presenting cell (i.e. PBMC-resident monocytes and monocyte-derived dendritic cells maturated with Poly I:C and PGE-2 based cocktails) on ELISpot assay performance and defined an optimized dendritic cell-based ELISpot protocol. This protocol is suitable for monitoring immune responses directed to protein antigens with higher sensitivity than the standard procedure.
    MeSH term(s) Antigen Presentation ; Antigens/immunology ; Cancer Vaccines/immunology ; Cells, Cultured ; Coculture Techniques ; Dendritic Cells/drug effects ; Dendritic Cells/immunology ; Dinoprostone/pharmacology ; Enzyme-Linked Immunospot Assay/standards ; Humans ; Interferon-gamma Release Tests/standards ; Interleukin-10/metabolism ; Interleukin-12/metabolism ; Leukocytes, Mononuclear/drug effects ; Leukocytes, Mononuclear/immunology ; Limit of Detection ; Monitoring, Immunologic/standards ; Poly I-C/pharmacology ; Sensitivity and Specificity ; T-Lymphocytes/immunology ; Time Factors
    Chemical Substances Antigens ; Cancer Vaccines ; IL10 protein, human ; Interleukin-10 (130068-27-8) ; Interleukin-12 (187348-17-0) ; Dinoprostone (K7Q1JQR04M) ; Poly I-C (O84C90HH2L)
    Language English
    Publishing date 2013-05-31
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 120142-6
    ISSN 1872-7905 ; 0022-1759
    ISSN (online) 1872-7905
    ISSN 0022-1759
    DOI 10.1016/j.jim.2013.03.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Usage of standardized antigen-presenting cells improves ELISpot performance for complex protein antigens

    Navarrete, Marcelo A / Bertinetti-Lapatki, Cristina / Michelfelder, Ines / Veelken, Hendrik

    Journal of immunological methods. 2013 May 31, v. 391, no. 1-2

    2013  

    Abstract: The enzyme-linked immunospot (ELISpot) assay is a widely used method for immune monitoring in cancer immunotherapy trials. In the ELISpot assay, peripheral blood mononuclear cells (PBMC) are stimulated with specific antigens, and cytokines of interest ... ...

    Abstract The enzyme-linked immunospot (ELISpot) assay is a widely used method for immune monitoring in cancer immunotherapy trials. In the ELISpot assay, peripheral blood mononuclear cells (PBMC) are stimulated with specific antigens, and cytokines of interest produced by individual cells are detected. In the standard procedure, T cells rely for antigen presentation on other cells like the monocyte/macrophage population present among the PBMC. Whereas oligopeptides can be added directly to the ELISpot assay without the necessity of a pre-incubation step, protein antigens must be internalized and processed by antigen-presenting cells to accomplish efficient presentation via HLA class I or II. We have studied the impact of sources for different antigen-presenting cell (i.e. PBMC-resident monocytes and monocyte-derived dendritic cells maturated with Poly I:C and PGE-2 based cocktails) on ELISpot assay performance and defined an optimized dendritic cell-based ELISpot protocol. This protocol is suitable for monitoring immune responses directed to protein antigens with higher sensitivity than the standard procedure.
    Keywords T-lymphocytes ; antigen presentation ; antigens ; cytokines ; dendritic cells ; immune response ; immunotherapy ; macrophages ; monitoring ; monocytes ; oligopeptides
    Language English
    Dates of publication 2013-0531
    Size p. 146-153.
    Publishing place Elsevier B.V.
    Document type Article
    ZDB-ID 120142-6
    ISSN 1872-7905 ; 0022-1759
    ISSN (online) 1872-7905
    ISSN 0022-1759
    DOI 10.1016/j.jim.2013.03.004
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  6. Article ; Online: Combining In Vivo and Organotypic In Vitro Approaches to Assess the Human Relevance of Basimglurant (RG7090), a Potential CAR Activator.

    Nudischer, Ramona / Renggli, Kasper / Bertinetti-Lapatki, Cristina / Hoflack, Jean-Christophe / Flint, Nicholas / Sewing, Sabine / Pedersen, Lykke / Schadt, Simone / Higgins, Larry G / Vardy, Audrey / Lenz, Barbara / Gand, Laurent / Boess, Franziska / Elcombe, Barbara M / Hierlemann, Andreas / Roth, Adrian B

    Toxicological sciences : an official journal of the Society of Toxicology

    2020  Volume 176, Issue 2, Page(s) 329–342

    Abstract: Basimglurant (RG7090), a small molecule under development to treat certain forms of depression, demonstrated foci of altered hepatocytes in a long-term rodent-toxicity study. Additional evidence pointed toward the activation of the constitutive ... ...

    Abstract Basimglurant (RG7090), a small molecule under development to treat certain forms of depression, demonstrated foci of altered hepatocytes in a long-term rodent-toxicity study. Additional evidence pointed toward the activation of the constitutive androstane receptor (CAR), an established promoter of nongenotoxic and rodent-specific hepatic tumors. This mode of action and the potential human relevance was explored in vivo using rodent and cynomolgus monkey models and in vitro using murine and human liver spheroids. Wild type (WT) and CAR/pregnane X receptor (PXR) knockout mice (CAR/PXR KO) were exposed to RG7090 for 8 consecutive days. Analysis of liver lysates revealed induction of Cyp2b mRNA and enzyme activity, a known activation marker of CAR, in WT but not in CAR/PXR KO animals. A series of proliferative genes were upregulated in WT mice only, and immunohistochemistry data showed increased cell proliferation exclusively in WT mice. In addition, primary mouse liver spheroids were challenged with RG7090 in the presence or absence of modified antisense oligonucleotides inhibiting CAR and/or PXR mRNA, showing a concentration-dependent Cyp2b mRNA induction only if CAR was not repressed. On the contrary, neither human liver spheroids nor cynomolgus monkeys exposed to RG7090 triggered CYP2B mRNA upregulation. Our data suggested RG7090 to be a rodent-specific CAR activator, and that CAR activation and its downstream processes were involved in the foci of altered hepatocytes formation detected in vivo. Furthermore, we demonstrated the potential of a new in vitro approach using liver spheroids and antisense oligonucleotides for CAR knockdown experiments, which could eventually replace in vivo investigations using CAR/PXR KO mice.
    MeSH term(s) Animals ; Hepatocytes ; Humans ; Imidazoles/pharmacology ; Liver ; Macaca fascicularis ; Mice ; Mice, Inbred C57BL ; Organoids ; Pyridines/pharmacology ; Receptors, Cytoplasmic and Nuclear/agonists ; Receptors, Steroid
    Chemical Substances 2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine ; Imidazoles ; Pyridines ; Receptors, Cytoplasmic and Nuclear ; Receptors, Steroid ; constitutive androstane receptor (438XLITDI3)
    Language English
    Publishing date 2020-05-26
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1420885-4
    ISSN 1096-0929 ; 1096-6080
    ISSN (online) 1096-0929
    ISSN 1096-6080
    DOI 10.1093/toxsci/kfaa076
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Temporal Patterns of Novel Circulating Biomarkers in IL-2-mediated Vascular Injury in the Rat.

    Keirstead, Natalie D / Bertinetti-Lapatki, Cristina / Knapp, Denise / Albassam, Mudher / Hughes, Valerie / Hong, Feng / Roth, Adrian B / Mikaelian, Igor

    Toxicologic pathology

    2015  Volume 43, Issue 7, Page(s) 984–994

    Abstract: Recombinant interleukin-2 (rIL-2) administration in oncology indications is hampered by vascular toxicity, which presents as a vascular leak syndrome. We used this aspect of the toxicity of rIL-2 to evaluate candidate biomarkers of drug-induced vascular ... ...

    Abstract Recombinant interleukin-2 (rIL-2) administration in oncology indications is hampered by vascular toxicity, which presents as a vascular leak syndrome. We used this aspect of the toxicity of rIL-2 to evaluate candidate biomarkers of drug-induced vascular injury (DIVI) in rats given 0.36 mg/kg rIL-2 daily. Groups of rats were given either 2 or 5 doses of rIL-2 or 5 doses of rIL-2 followed by a 7-day recovery. The histomorphologic lexicon and grading scheme developed by the Vascular Injury Working Group of the Predictive Safety Testing Consortium of the Critical Path Institute were utilized to enable semiquantitative integration with circulating biomarker levels. The administration of rIL-2 was associated with time-dependent endothelial cell hyperplasia and hypertrophy and perivascular inflammation that correlated with increases in circulating angiopoietin-2, lipocalin-2, monocyte chemotactic protein-1, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor A, E-selectin, and chemokine (C-X-C motif) ligand-1, and the microRNAs miR-21, miR-132, and miR-155. The dose groups were differentially identified by panels comprising novel candidate biomarkers and traditional hematologic parameters. These results identify biomarkers of the early stages of DIVI prior to the onset of vascular smooth muscle necrosis.
    MeSH term(s) Animals ; Biomarkers/blood ; Immunohistochemistry ; In Situ Hybridization ; Interleukin-2/toxicity ; Male ; Rats ; Rats, Wistar ; Real-Time Polymerase Chain Reaction ; Recombinant Proteins/toxicity ; Vascular System Injuries/blood ; Vascular System Injuries/chemically induced
    Chemical Substances Biomarkers ; Interleukin-2 ; Recombinant Proteins
    Language English
    Publishing date 2015-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 841009-4
    ISSN 1533-1601 ; 0192-6233
    ISSN (online) 1533-1601
    ISSN 0192-6233
    DOI 10.1177/0192623315601245
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Isotype-switched follicular lymphoma displays dissociation between activation-induced cytidine deaminase expression and somatic hypermutation.

    Scherer, Florian / Navarrete, Marcelo A / Bertinetti-Lapatki, Cristina / Boehm, Joachim / Schmitt-Graeff, Annette / Veelken, Hendrik

    Leukemia & lymphoma

    2015  Volume 57, Issue 1, Page(s) 151–160

    Abstract: In B-cells, activation-induced cytidine deaminase (AID) is required for somatic hypermutation (SHM) and class switch recombination (CSR) of immunoglobulin genes. AID introduces mutations in immunoglobulin variable regions (IGV) during B-cell receptor ... ...

    Abstract In B-cells, activation-induced cytidine deaminase (AID) is required for somatic hypermutation (SHM) and class switch recombination (CSR) of immunoglobulin genes. AID introduces mutations in immunoglobulin variable regions (IGV) during B-cell receptor affinity maturation, but may also introduce aberrant mutations into non-immunoglobulin genes, most commonly BCL6. Follicular lymphoma (FL) B-cells constitutively express AID and undergo CSR, SHM and aberrant SHM. We have studied AID expression, the presence of SHM mutations, CSR, and aberrant SHM in BCL6 in a cohort of 75 FL patients. Whereas IgM-expressing (non-switched) FL were characterized by an expected positive correlation between AID and IGV and BCL6 mutations, isotype-switched FL showed dissociation between AID expression and aberrant SHM, and inverse correlation between SHM and AID expression. Our results unveil two manifest biological subgroups of FL and indicate that the specific dissociation between AID and SHM after isotype switch may correlate with the clinical outcome of this heterogeneous disease.
    MeSH term(s) Adult ; Aged ; Biopsy ; Cytidine Deaminase/genetics ; DNA-Binding Proteins/genetics ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Immunoglobulin Class Switching/genetics ; Immunoglobulin Heavy Chains/genetics ; Immunoglobulin Variable Region/genetics ; Lymphoma, Follicular/diagnosis ; Lymphoma, Follicular/genetics ; Lymphoma, Follicular/therapy ; Male ; Middle Aged ; Neoplasm Grading ; Proto-Oncogene Proteins c-bcl-6 ; Somatic Hypermutation, Immunoglobulin ; Transcriptional Activation ; Young Adult
    Chemical Substances BCL6 protein, human ; DNA-Binding Proteins ; Immunoglobulin Heavy Chains ; Immunoglobulin Variable Region ; Proto-Oncogene Proteins c-bcl-6 ; Cytidine Deaminase (EC 3.5.4.5)
    Language English
    Publishing date 2015-05-18
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.3109/10428194.2015.1037758
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia.

    Sewing, Sabine / Roth, Adrian B / Winter, Michael / Dieckmann, Andreas / Bertinetti-Lapatki, Cristina / Tessier, Yann / McGinnis, Claudia / Huber, Sylwia / Koller, Erich / Ploix, Corinne / Reed, John C / Singer, Thomas / Rothfuss, Andreas

    PloS one

    2017  Volume 12, Issue 11, Page(s) e0187574

    Abstract: Single-stranded oligonucleotides (ON) comprise a promising therapeutic platform that enables selective modulation of currently undruggable targets. The development of novel ON drug candidates has demonstrated excellent efficacy, but in certain cases also ...

    Abstract Single-stranded oligonucleotides (ON) comprise a promising therapeutic platform that enables selective modulation of currently undruggable targets. The development of novel ON drug candidates has demonstrated excellent efficacy, but in certain cases also some safety liabilities were reported. Among them are events of thrombocytopenia, which have recently been evident in late stage trials with ON drugs. The underlying mechanisms are poorly understood and the risk for ON candidates causing such events cannot be sufficiently assessed pre-clinically. We investigated potential thrombocytopenia risk factors of ONs and implemented a set of in vitro assays to assess these risks. Our findings support previous observations that phosphorothioate (PS)-ONs can bind to platelet proteins such as platelet collagen receptor glycoprotein VI (GPVI) and activate human platelets in vitro to various extents. We also show that these PS-ONs can bind to platelet factor 4 (PF4). Binding to platelet proteins and subsequent activation correlates with ON length and connected to this, the number of PS in the backbone of the molecule. Moreover, we demonstrate that locked nucleic acid (LNA) ribosyl modifications in the wings of the PS-ONs strongly suppress binding to GPVI and PF4, paralleled by markedly reduced platelet activation. In addition, we provide evidence that PS-ONs do not directly affect hematopoietic cell differentiation in culture but at higher concentrations show a pro-inflammatory potential, which might contribute to platelet activation. Overall, our data confirm that certain molecular attributes of ONs are associated with a higher risk for thrombocytopenia. We propose that applying the in vitro assays discussed here during the lead optimization phase may aid in deprioritizing ONs with a potential to induce thrombocytopenia.
    Language English
    Publishing date 2017
    Publishing country United States
    Document type Journal Article
    ISSN 1932-6203
    ISSN (online) 1932-6203
    DOI 10.1371/journal.pone.0187574
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies.

    Kerns, S Jordan / Belgur, Chaitra / Petropolis, Debora / Kanellias, Marianne / Barrile, Riccardo / Sam, Johannes / Weinzierl, Tina / Fauti, Tanja / Freimoser-Grundschober, Anne / Eckmann, Jan / Hage, Carina / Geiger, Martina / Ng, Patrick Ray / Tien-Street, William / Manatakis, Dimitris V / Micallef, Virginie / Gerard, Regine / Bscheider, Michael / Breous-Nystrom, Ekaterina /
    Schneider, Anneliese / Giusti, Anna Maria / Bertinetti-Lapatki, Cristina / Grant, Heather Shannon / Roth, Adrian B / Hamilton, Geraldine A / Singer, Thomas / Karalis, Katia / Moisan, Annie / Bruenker, Peter / Klein, Christian / Bacac, Marina / Gjorevski, Nikolce / Cabon, Lauriane

    eLife

    2021  Volume 10

    Abstract: Traditional drug safety assessment often fails to predict complications in humans, especially when the drug targets the immune system. Here, we show the unprecedented capability of two human Organs-on-Chips to evaluate the safety profile of T-cell ... ...

    Abstract Traditional drug safety assessment often fails to predict complications in humans, especially when the drug targets the immune system. Here, we show the unprecedented capability of two human Organs-on-Chips to evaluate the safety profile of T-cell bispecific antibodies (TCBs) targeting tumor antigens. Although promising for cancer immunotherapy, TCBs are associated with an on-target, off-tumor risk due to low levels of expression of tumor antigens in healthy tissues. We leveraged in vivo target expression and toxicity data of TCBs targeting folate receptor 1 (FOLR1) or carcinoembryonic antigen (CEA) to design and validate human immunocompetent Organs-on-Chips safety platforms. We discovered that the Lung-Chip and Intestine-Chip could reproduce and predict target-dependent TCB safety liabilities, based on sensitivity to key determinants thereof, such as target expression and antibody affinity. These novel tools broaden the research options available for mechanistic understandings of engineered therapeutic antibodies and assessing safety in tissues susceptible to adverse events.
    MeSH term(s) Animals ; Antibodies, Bispecific/adverse effects ; Female ; HEK293 Cells ; HeLa Cells ; Humans ; Immunotherapy/methods ; Lab-On-A-Chip Devices/statistics & numerical data ; Mice ; T-Lymphocytes/immunology
    Chemical Substances Antibodies, Bispecific
    Language English
    Publishing date 2021-08-11
    Publishing country England
    Document type Evaluation Study ; Journal Article
    ZDB-ID 2687154-3
    ISSN 2050-084X ; 2050-084X
    ISSN (online) 2050-084X
    ISSN 2050-084X
    DOI 10.7554/eLife.67106
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top